EP3444261A1 — 2,2-difluoropropionamide derivative of bardoxolone methyl, pharmaceutical compositions and polymorphs thereof for use in treating certain conditions
Assigned to Reata Pharmaceuticals Inc · Expires 2019-02-20 · 7y expired
What this patent protects
The present invention relates to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-l,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide and polymorphic forms and pharmaceutical composi…
USPTO Abstract
The present invention relates to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-l,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide and polymorphic forms and pharmaceutical compositions thereof for use in the treatment of cancer in combination with immunotherapy, for use in the treatment of conditions associated with oxidative stree caused by mitochondrial dysfunction and for use in the treatment of seizure disorders.
Drugs covered by this patent
- Skyclarys (OMAVELOXOLONE) · Biogen Us
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.